Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.

about

Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.

Item

http://www.wikidata.org/entity/Q48254283

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Severe hypoglycaemia from repa ...... report and literature review.

@en

Severe hypoglycaemia from repa ...... report and literature review.

@nl

type

Item

label

Severe hypoglycaemia from repa ...... report and literature review.

@en

Severe hypoglycaemia from repa ...... report and literature review.

@nl

prefLabel

Severe hypoglycaemia from repa ...... report and literature review.

@en

Severe hypoglycaemia from repa ...... report and literature review.

@nl

P1476

Severe hypoglycaemia from repa ...... report and literature review.

@en

P2093

M Khamaisi

http://www.w3.org/2001/XMLSchema#string

P2860

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

Clinical pharmacokinetics and pharmacodynamics of repaglinide.

Cyclosporine markedly raises the plasma concentrations of repaglinide.

Severe hypoglycemia from clarithromycin-repaglinide drug interaction.

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.

Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.

P304

1214-1215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-5491.2012.03631.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22414218

http://www.w3.org/2001/XMLSchema#string

P921

hypoglycemia